New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2012
12:16 EDTAMTG, GS, DNN, JNJ, ZNGA, FSLR, KOOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, as the International Monetary Fund raised its view on U.S. and global growth prospects. Stock futures spurted higher during the pre-market trading session following the IMF’s increase in its growth projections. Also helping push the futures upward were positive earnings reports from some of the country’s largest corporations. The futures action led to a higher open for the broader market. The market pared its opening gains during the first 30 minutes of trading but then resumed it march higher and sat near its daily highs near noon... ECONOMIC EVENTS: Domestically, housing starts for the month of March decreased 5.8%, versus expectations of an increase of 1.0%. The annual run rate came in at 654,000 units, versus the consensus estimate of 750,000. The number of building permits issued, however, rose 4.5% to 747,000, versus expectations of a decrease of 0.7% to 710,000. Industrial production was reportedly flat in March, versus expectations for a 0.3% increase. Capacity utilization was in line with forecasts at at 78.6%. Also, the International Monetary Fund said it sees world output growing 3.5% in 2012, raising its projection for United States growth to 2.1%. The IMF said it sees growth in China slowing to 8.2% and real GDP in the euro area contracting in the first half of 2012 but then recovering... COMPANY NEWS: All but one Dow component was higher near noon, led by shares of Coca Cola (KO), which rose 2.7% following its better than expected earnings report. The only Dow decliner was Johnson & Johnson (JNJ), which reported adjusted earnings that beat expectations but revenues below the Street's forecast... Goldman Sachs's (GS) stock was nearly flat in spite of earnings and revenue that beat expectations and an increase in its quarterly dividend to 46c from 35c... MAJOR MOVERS: Among the notable gainers were First Solar (FSLR), up nearly 13%, after it announced plans to cut its global workforce by approximately 2,000 positions, or about 30%, in response to conditions in Europe, and Denison Mines (DNN), up almost 15%, after agreeing to sell its mining assets and operations located in the United States to Energy Fuels. Noteworthy losers included Apollo Residential Mortgage (AMTG), down 6%, after filing to sell 13.9M shares of its common stock, and Zynga (ZNGA), down over 3%, amid reports that its newly acquired Draw Something game has seen its daily active use fall off... INDICES: Near noon, the Dow was up 181.57, or 1.41%, to 13,102.98; the Nasdaq was up 50.58, or 1.69%, to 3,038.98; and the S&P 500 was up 19.24, or 1.40%, to 1,388.81.
News For KO;JNJ;GS;FSLR;DNN;AMTG;ZNGA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 22, 2015
07:00 EDTGSGoldman Sachs making major investments despite Volcker Rule, NY Times says
Goldman Sachs has been making significant investments with its own money despite the Volcker Rule ,which many had assumed would prevent such deals, according to The New York Times. Goldman has managed to find ways to make major deals with its own funds without appearing to violate the law, even as its competitors avoid such transactions, the newspaper stated. Reference Link
06:13 EDTGSGoldman Sachs to lead $56M investment in Antuit Holdings, WSJ reports
Subscribe for More Information
January 21, 2015
16:35 EDTJNJMinerva reports positive Phase 1 data with MIN-202
Minerva Neurosciences (NERV) announced that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder, or MDD. Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features. The three Phase 1 studies were conducted by Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), as part of a collaboration to develop MIN-202 with Minerva that was facilitated by Johnson & Johnson Innovation Ltd in London.
10:16 EDTJNJLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:23 EDTJNJOn The Fly: Closing Wrap
Stocks began the session in positive territory, but the major averages were unable to hold their early gains. Lackluster earnings reports, the falling price of oil, and lowered global growth expectations appeared to be too much to overcome after a three day holiday weekend. The Dow led the way lower and had losses of more than 100 points before reversing and slowly paring its losses. Late in the day the averages made it back to positive ground, as investors await the next round of earnings due out after the close. ECONOMIC EVENTS: In the U.S., the NAHB homebuilder sentiment index fell to 57 in January, missing expectations for it to hold steady at 58. In China, Q4 GDP growth of 7.3% came in slightly better than expected, though that puts the nation's 2014 GDP growth at 7.4%, which was the lowest reported in 24 years. Of note, the International Monetary Fund cut its forecast for global growth in 2015 to 3.5% and in 2016 to 3.7%, which were both revised down by 0.3% relative to the organization's October 2014 outlook. COMPANY NEWS: Shares of Johnson & Johnson (JNJ) led all decliners on the Dow Jones Industrial Average with a drop of $2.75, or 2.64%, to $101.29 after its Q4 earnings were nearly in-line and its FY15 outlook failed to spur buying of the stock... Morgan Stanley (MS) declined 14c, or 0.4%, to $34.75 after the firm became the latest in the financial space to report headline earnings that missed expectations. MAJOR MOVERS: Among the notable gainers was Smith & Wesson (SWHC), which rose $1.65, or 16.47%, to $11.67 after the gunmaker increased its financial guidance and said it has seen recent, positive trends in the primary indicators it uses to assess its business and the consumer firearm market. Also higher was Orbitz Worldwide (OWW), which jumped 79c, or 8.62%, to $9.95 after Bloomberg reported that the online travel agency is working with an adviser to contact potential buyers and has drawn interest from private-equity funds and "other Internet companies." Among the noteworthy losers was FXCM (FXCM), which plunged $11.03, or 87.33%, to $1.60 after the stock reopened following the company struck a $300M rescue agreement with Leucadia (LUK) and gave further details on that deal over the weekend. Also lower were shares of Redbox owner Outerwall (OUTR), which fell $15.72, or 20.21%, to $62.05 after the company announced that its CEO had stepped down. INDEXES: The Dow rose 3.66, or 0.02%, to 17,515.23, the Nasdaq gained 20.46, or 0.44%, to 4,654.85, and the S&P 500 advanced 3.13, or 0.15%, to 2,022.55.
16:00 EDTJNJOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
13:08 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
11:03 EDTFSLRStocks with call strike movement; FSLR NE
First Solar (FSLR) January call option implied volatility increased 5% to 48, Noble Corp. (NE) June 18 call option implied volatility increased 9% to 53 according to IVolatility.
10:33 EDTJNJJohnson & Johnson falls post-earnings, levels to watch
Subscribe for More Information
09:48 EDTJNJJohnson & Johnson says eyeing options in orthopedics, surgical, vision care
Subscribe for More Information
09:38 EDTKOActive equity options trading
Subscribe for More Information
09:21 EDTJNJJ&J says negative impact of currency to be 'more significant' than expected
Says currency impact will be more significant in 1H than in 2H.
09:20 EDTJNJJ&J says 'comfortable' with models reflecting midpoint of FY EPS view
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson sees FY15 reported sales $75B-$76B
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson CEO says core businesses 'strong'
Johnson & Johnson (JNJ) providing sustainable, high quality healthcare "one of society's greatest challenges." Says core businesses "strong," positioned to continue expanding their leadership positions. CEO Alex Gorsky says company is changing the way it interacts with customers, evolving to be more "effective," "efficient." Says U.S. OTC consent decree requirements completed. Says in the process of developing a China lung center. Says still plans to take $1B out of P&L in next three years. Says aims to bring Ebola vaccine to market "as fast as possible." Says "well-positioned" for long-term. Says currency headwinds have increased "quite substantially," negatively impacting sales, earnings to greater extent than company had anticipated. Sees Depomed (DEPO) transaction closing in Q2. Expects R&D tax credit will be renewed in 2015. If R&D tax credit is approved, sees effective tax rate for 2015 of approx. 20%-21%. Sees operational sales growth for 2015 approx. 6%. Says Wall Street forecasts may not adequately reflect likely negative impact in 2015 of foreign exchange. Sees FY15 operational sales growth 1%-2% in constant currency. Comments made on the Q4 earnings conference call.
08:18 EDTJNJJohnson & Johnson sees 10 major Pharmaceuticals filings from 2013-2017
Sees 10 major filings, 25 line extensions in Pharmaceuticals expected between 2013-2017. Sees about 100 ongoing discovery projects, 50 novel compounds in early development, 5 breakthrough designations. Sees 30 major Medical Devices filings expected from 2014-2016, 20 key Consumer product launches expected global in 2015. Says near-term priorities include: Accelerating growth in Medical Devices through innovation, expanding market leadership in key consumer segments like OTC, Oral Care, Baby and Beauty. Comments from slides that will be presented on the Q4 earnings conference call.
07:52 EDTJNJJohnson & Johnson reports Q4 Pharmaceutical sales $8B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.12-$6.27, consensus $6.13
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
07:28 EDTGSTreasury Institute for Higher Education to hold a symposium
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use